Hamlet BioPharma (HAMLET) Q2 2026 earnings summary

Executive summary

• Achieved major milestones including completion of three Phase II studies in cancer, infection, and chronic pain, and secured drug production for Phase III studies.

• Positive FDA feedback supports pivotal Phase III study for Alpha1H in non-muscle invasive bladder cancer, with advanced preparations underway.

• Published successful Phase II results for non-antibiotic treatment of acute cystitis, showing efficacy comparable to antibiotics.

• Entered a partnering agreement with ImmunoForge for novel drug delivery technology for tuberculosis treatment.

• Ongoing global commercialization and partnership efforts, with a new CEO appointed to lead the next phase.

Financial highlights

• Net sales were KSEK 0 for both the quarter and first half, reflecting the pre-revenue stage.

• EBITDA for the quarter was KSEK -13,026 (previous year: -11,847); for the first half, KSEK -22,651 (previous year: -19,649).

• EBIT for the quarter was KSEK -15,579 (previous year: -14,481); for the first half, KSEK -27,739 (previous year: -24,917).

• Net result for the quarter was KSEK -15,431 (previous year: -14,387); for the first half, KSEK -27,588 (previous year: -24,651).

• Cash at period end was KSEK 16,638 (previous year: 30,416); equity/assets ratio was 83.6% (previous year: 92.8%).

Outlook and guidance

• Immediate goal is to conduct Phase III studies and obtain market approval for Alpha1H in bladder cancer.

• Actively exploring additional funding avenues and global partnerships for commercialization.

• Strategic focus on advancing preclinical assets and expanding the clinical pipeline.